| Stage |
Phase |
Principal Investigator |
Study prefix |
Study number |
Title (click hyperlink for more information) |
| I | Myron Czuczman, MD | I | 116907 | (Biogen Idec #114NH103) A Phase I, Single Center, Open Label Study to Evaluate the Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non Hodgkin's Lymphoma |
| Advanced | II | Francisco Hernandez, MD | I | 107507 | (MSKCC #05-098) Phase II Trial of Doxorubicin HCI Liposome Injection (Doxil) in Advanced Stage Cutaneous T-Cell Lymphoma Followed by Bexarotene (Targretin) |
| II | Myron Czuczman, MD | NCG / CALGB | 88206 | (CALGB 50403) A Randomized Phase II Trial of Maintenance vs Consolidation Bortezomib Therapy Following Aggressive Chemo-Immunotherapy and Autologous Stem Cell Transplant for Previously Untreated Mantle Cell |
| II | Francisco Hernandez, MD | I | 83106 | Phase II Clinical Trial of Rituximab in Combination with Pegfilgrastim in Patients with Indolent B-Cell (CD-20-Positive) Lymphoma |
| III | Myron Czuczman, MD | NCG / CALGB | 57305 | (CALGB 50303) Phase III Randomized Study of R-CHOP vs Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas |
| II | Myron Czuczman, MD | I | 136508 | A Phase II Study of VDR (Velcade, Doxil and Rituxan) in Relapsed/Refractory Diffuse Large B-cell Lymphoma |
| II | Myron Czuczman, MD | NCG / CALGB | 126308 | (CALGB 50501) A Phase II Trial of Bortezomib (NSC #681239) + Lenalidomide (Revlimid, CC-5013) (NSC # 703813) For Relapsed / Refractory Mantle Cell Lymphoma |
| II | Myron Czuczman, MD | PH | 147508 | (GSK OMB 110927) A Single Arm, Safety and Efficacy Study of Ofatumumab in Combination with ICE or DHAP Chemotherapy in Relapsed or Refractory Aggressive Lymphoma Prior to Autologous Stem Cell Transplanation |
| I | Asher Chanan Khan, MD | PH | 147608 | (C14003) Phase I Trial of MLN8237 a novel Arora Kinase Inhibitor in Patients with Hematologic Malignancy |
| II | Francisco Hernandez, MD | PH | 152209 | (SNDX-275-0501) A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patients With relapsed Or Refractory Hodgkin's Lymphoma |